Leen Kawas has built her career at the intersection of science, entrepreneurship, and investment. As co-founder and managing general partner of Propel Bio Partners, she now channels that experience into supporting life science companies with the potential to transform patient care. Her vision for the venture fund is shaped not only by her track record in biotech leadership but also by a conviction that the right combination of capital, expertise, and strategic support can accelerate breakthroughs from the lab to the clinic.
Before founding Propel Bio Partners, Kawas co-founded and led Athira Pharma, guiding it from an early-stage neuroscience company to a Nasdaq-listed biopharmaceutical firm. Under her leadership, Athira advanced late-stage clinical programs and raised over $400 million—making Leen Kawas one of only 22 women founders in the United States to take a company public. That experience gave her a first-hand view of the challenges and opportunities life science entrepreneurs face, from securing funding to navigating the complex regulatory environment.
With Propel Bio Partners, Kawas set out to build the kind of investor she wished she had when leading a biotech startup. The fund’s focus is not just on writing checks but on forming active partnerships with portfolio companies. This means working alongside management teams to refine development strategies, strengthen operational capacity, and connect with key stakeholders in the scientific and medical communities. In her view, the most impactful venture capital combines financial investment with targeted mentorship and industry insight.
Kawas is intentional about where the fund directs its resources. Propel Bio Partners prioritises companies with strong scientific foundations, clear paths to clinical validation, and management teams that combine vision with execution capability. She believes that rigorous due diligence—evaluating not only the underlying technology but also its potential impact on patients—is essential for both returns and societal value. The goal is to back innovations that can make a meaningful difference in health outcomes, whether through novel therapeutics, diagnostics, or enabling technologies.
Her approach to portfolio building is also shaped by a recognition that breakthrough science often emerges from diverse sources. Kawas advocates for expanding the traditional geographic and demographic boundaries of biotech investment, identifying opportunities in underrepresented regions and supporting founders from a wide range of backgrounds. She sees this as both a moral imperative and a competitive advantage, as it broadens the pool of ideas and perspectives driving innovation.
Another hallmark of the Propel Bio Partners model is long-term commitment. Kawas understands that life science companies operate on timelines that can span years or even decades. Early-stage ventures, particularly those developing novel therapies, require patient capital and investors who can weather the inevitable setbacks of drug development. By aligning investment horizons with the realities of the sector, she aims to give portfolio companies the stability they need to advance their programs through critical inflection points.
Kawas also places strong emphasis on strategic networking. Propel Bio Partners leverages her extensive relationships across biotech, pharma, academia, and the investment community to open doors for portfolio companies. Whether it’s facilitating introductions to potential partners, assembling scientific advisory boards, or helping recruit top-tier talent, she views these connections as vital to scaling innovation effectively.
The venture fund’s mission is further informed by Kawas’s scientific background. Trained as a pharmacist and holding a PhD in molecular pharmacology, she brings a depth of technical understanding that enables her to engage with founders on the specifics of their science. This scientific literacy helps bridge the gap between investors and innovators, ensuring that investment decisions are grounded in both market potential and biological feasibility. Kawas also recently completed an interview on Principal Post further highlighting her beliefs and vision for the future.
Kawas’s broader goal is to create a virtuous cycle: successful exits from portfolio companies generate returns that can be reinvested into new ventures, sustaining a pipeline of innovation. In doing so, she hopes to contribute to an ecosystem where more groundbreaking ideas can find the funding and guidance they need to reach patients.
Her leadership at Propel Bio Partners reflects a belief that the venture capital model can be a force for both financial and societal good when applied with discipline and purpose. For Kawas, building a venture fund for life science breakthroughs is not just about identifying the next high-growth company; it is about fostering the conditions where transformative science can thrive and make an impact on human health.
As she looks ahead, Kawas is optimistic about the opportunities in life sciences, from advancements in gene therapy and immuno-oncology to new approaches in neuroscience and rare diseases. She is equally aware of the responsibility that comes with investing in these areas, where the stakes include not only capital but the lives and well-being of patients. For Leen Kawas, that responsibility is what makes the work worth doing—and what drives her commitment to building a venture fund that serves both science and society.
To learn more about Kawas’ career check out her profile on Crunchbase: